Skip to menu Skip to content Skip to footer

2025

Conference Publication

Efficacy of Ethambutol Rechallenge in Patients With Prior Ethambutol-induced Optic Toxicity for the Treatment of Mycobacterium Avium Complex Pulmonary Disease

Yeo, B., Goh, F. and Thomson, R. (2025). Efficacy of Ethambutol Rechallenge in Patients With Prior Ethambutol-induced Optic Toxicity for the Treatment of Mycobacterium Avium Complex Pulmonary Disease. ATS International Conference, San Francisco, CA United States, 16-21 May 2025. New York, NY United States: American Thoracic Society.

Efficacy of Ethambutol Rechallenge in Patients With Prior Ethambutol-induced Optic Toxicity for the Treatment of Mycobacterium Avium Complex Pulmonary Disease

2025

Conference Publication

Prevalence of Nausea and Vomiting and Anti-emetic Use in the Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (FORMaT) Trial

Thomson, R., Hicks, D., Rice, M., Jong, T., Joshi, S., Wang, X., Burke, A.J., Grimwood, K., Bell, S., Clark, J. and Wainwright, C.E. (2025). Prevalence of Nausea and Vomiting and Anti-emetic Use in the Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (FORMaT) Trial. ATS International Conference, San Francisco, CA United States, 16-21 May 2025. New York, NY United States: American Thoracic Society. doi: 10.1164/ajrccm.2025.211.abstracts.a7277

Prevalence of Nausea and Vomiting and Anti-emetic Use in the Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (FORMaT) Trial

2025

Conference Publication

Adverse Events Related to Study Drugs in Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (Format) Trial

Thomson, R., Hicks, D., Rice, M., Jong, T., Gailer, N., Joshi, S., Wang, X., Burke, A. J., Grimwood, K., Bell, S., Clark, J. and Wainwright, C. E. (2025). Adverse Events Related to Study Drugs in Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (Format) Trial. 52nd Critical Care Congress of the Society of Critical Care Medicine (SCCM), San Francisco, CA United States, 21-24 January 2023. New York, NY United States: American Thoracic Society.

Adverse Events Related to Study Drugs in Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (Format) Trial

2025

Conference Publication

Adverse Events Related to Study Drugs in Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (Format) Trial

Thomson, R., Hicks, D., Rice, M., Jong, T., Gailer, N., Joshi, S., Wang, X., Burke, A.J., Grimwood, K., Bell, S., Clark, J. and Wainwright, C.E. (2025). Adverse Events Related to Study Drugs in Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (Format) Trial. ATS International Conference, San Francisco, CA United States, 16-21 May 2025. New York, NY United States: American Thoracic Society. doi: 10.1164/ajrccm.2025.211.abstracts.a7278

Adverse Events Related to Study Drugs in Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (Format) Trial

2025

Conference Publication

Gut Microbiome Signatures Discriminate Nontuberculous Mycobacterial Pulmonary Disease Patients Requiring Treatment From Those With Stable Disease

Thompson, R., Lim, Y., Goh, F., Blumenthal, A., Morrison, M. and Thomson, R. (2025). Gut Microbiome Signatures Discriminate Nontuberculous Mycobacterial Pulmonary Disease Patients Requiring Treatment From Those With Stable Disease. ATS International Conference, San Francisco, CA United States, 16-21 May 2025. New York, NY United States: American Thoracic Society.

Gut Microbiome Signatures Discriminate Nontuberculous Mycobacterial Pulmonary Disease Patients Requiring Treatment From Those With Stable Disease

2025

Conference Publication

Real-world Experience With Inhaled Liposomal Amikacin Suspension for Treatment of Nontuberculous Mycobacterial Pulmonary Disease

Twining, M., Kang, S., Riddles, T., Evans, I., Burke, A. J. and Thomson, R. (2025). Real-world Experience With Inhaled Liposomal Amikacin Suspension for Treatment of Nontuberculous Mycobacterial Pulmonary Disease. ATS International Conference, San Francisco, CA United States, 16-21 May 2025. New York, NY United States: American Thoracic Society.

Real-world Experience With Inhaled Liposomal Amikacin Suspension for Treatment of Nontuberculous Mycobacterial Pulmonary Disease

2025

Conference Publication

Real-world Experience With Inhaled Liposomal Amikacin Suspension for Treatment of Nontuberculous Mycobacterial Pulmonary Disease

Twining, M., Kang, S., Riddles, T., Evans, I., Burke, A.J. and Thomson, R. (2025). Real-world Experience With Inhaled Liposomal Amikacin Suspension for Treatment of Nontuberculous Mycobacterial Pulmonary Disease. ATS International Conference, San Francisco, CA United States, 16-21 May 2025. New York, NY United States: American Thoracic Society. doi: 10.1164/ajrccm.2025.211.abstracts.a5444

Real-world Experience With Inhaled Liposomal Amikacin Suspension for Treatment of Nontuberculous Mycobacterial Pulmonary Disease

2025

Conference Publication

Prevalence of Nausea and Vomiting and Anti-emetic Use in the Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (FORMaT) Trial

Thomson, R., Hicks, D., Rice, M., Jong, T., Joshi, S., Wang, X., Burke, A. J., Grimwood, K., Bell, S., Clark, J. and Wainwright, C. E. (2025). Prevalence of Nausea and Vomiting and Anti-emetic Use in the Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (FORMaT) Trial. 52nd Critical Care Congress of the Society of Critical Care Medicine (SCCM), San Francisco, CA United States, 21-24 January 2023. New York, NY United States: American Thoracic Society.

Prevalence of Nausea and Vomiting and Anti-emetic Use in the Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (FORMaT) Trial

2025

Conference Publication

The aetiology and epidemiology of nontuberculous mycobacteria (NTM) in Australians with CF

Duplancic, C., Alene, K., Thomson, R., Wainwright, C., Rogers, G., Clements, A., Floto, A. and Bell, S. (2025). The aetiology and epidemiology of nontuberculous mycobacteria (NTM) in Australians with CF. TSANZSRS Annual Scientific meeting 2025, Adelaide, SA Australia, 21-25 March 2025. Richmond, VIC Australia: John Wiley & Sons.

The aetiology and epidemiology of nontuberculous mycobacteria (NTM) in Australians with CF

2025

Conference Publication

Adverse events related to study drugs in finding the optimal regimen for mycobacterium abscessus treatment (format) trial

Hicks, D., Rice, M., Jong, T., Gailer, N., Joshi, S., Wang, X., Thomson, R., Burke, A., Grimwood, K., Bell, S., Clark, J. and Wainwright, C. (2025). Adverse events related to study drugs in finding the optimal regimen for mycobacterium abscessus treatment (format) trial. TSANZSRS Annual Scientific meeting 2025, Adelaide, SA Australia, 21-25 March 2025. Richmond, VIC Australia: John Wiley & Sons.

Adverse events related to study drugs in finding the optimal regimen for mycobacterium abscessus treatment (format) trial

2024

Conference Publication

Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: Results of two randomized double-blind placebo-controlled phase 3 trials assessing safety and efficacy over 12 months

Haworth, Charles, Shteinberg, Michal, Winthrop, Kevin, Barker, Alan, Blasi, Francesco, Dimakou, Katerina, Morgan, Lucy, O'Donnell, Anne, Ringhausen, Felix, Sibila, Oriol, Thomson, Rachel, Carroll, Kevin, Pontenani, Federica, Castellani, Paola and Chalmers, James (2024). Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: Results of two randomized double-blind placebo-controlled phase 3 trials assessing safety and efficacy over 12 months. 2024 ERS Congress, Vienna, Austria, 7–11 September 2024. Sheffield, United Kingdom: European Respiratory Society. doi: 10.1183/13993003.congress-2024.rct5390

Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: Results of two randomized double-blind placebo-controlled phase 3 trials assessing safety and efficacy over 12 months

2024

Conference Publication

Nontuberculous mycobacteria (NTM) in Australians with cystic fibrosis (CF): A national study

Duplancic, Christine, Wainwright, Claire, Thomson, Rachel, Rogers, Geraint, Clements, Archie, Floto, Andre and Bell, Scott (2024). Nontuberculous mycobacteria (NTM) in Australians with cystic fibrosis (CF): A national study. 15th Australasian Cystic Fibrosis Conference, Brisbane, QLD, Australia, 2–4 August 2024. Richmond, VIC, Australia: John Wiley & Sons.

Nontuberculous mycobacteria (NTM) in Australians with cystic fibrosis (CF): A national study

2024

Conference Publication

Developing a pharmacovigilance framework for an investigator led, non-commercial international adaptive platform trial

Rice, Megan, Hicks, Daniel, Jong, Tiffany, Gailer, Nicolas, Joshi, Sri, Stevens, Luke, Lee, Kate, Thomson, Rachel, Burke, Andrew, Grimwood, Keith, Bell, Scott, Clark, Julia and Wainwright, Claire E. (2024). Developing a pharmacovigilance framework for an investigator led, non-commercial international adaptive platform trial. 15th Australasian Cystic Fibrosis Conference, Brisbane, QLD, Australia, 2–4 August 2024. Richmond, VIC, Australia: John Wiley & Sons.

Developing a pharmacovigilance framework for an investigator led, non-commercial international adaptive platform trial

2024

Conference Publication

Developing a pharmacovigilance framework for an investigator-led, non-commercial platform trial – finding the optimal regimen for Mycobacterium abscessus treatment (FORMaT)

Hicks, D., Jong, T., Rice, M., Gailer, N., Joshi, S., Stevens, L., Lee, K., Thomson, R., Burke, A., Grimwood, K., Bell, S., Clark, J. and Wainwright, C.E. (2024). Developing a pharmacovigilance framework for an investigator-led, non-commercial platform trial – finding the optimal regimen for Mycobacterium abscessus treatment (FORMaT). 47th European Cystic Fibrosis Conference, Glasgow, United Kingdom, 5-8 June 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/s1569-1993(24)00244-3

Developing a pharmacovigilance framework for an investigator-led, non-commercial platform trial – finding the optimal regimen for Mycobacterium abscessus treatment (FORMaT)

2024

Conference Publication

Validation of the BACES Severity Scoring System in an Australian Cohort of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Patients 

Mishiro, K., Ballard, E., Goh, F. and Thomson, R. (2024). Validation of the BACES Severity Scoring System in an Australian Cohort of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Patients . American Thoracic Society International Conference 2024, San Diego, CA United States, 17-22 May 2024. New York, NY United States: American Thoracic Society. doi: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a3158

Validation of the BACES Severity Scoring System in an Australian Cohort of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Patients 

2024

Conference Publication

Mycobacteria acquisition from potable water

Ramsay, K., Smith, K., Carter, R., Clayton, M., Thomson, R. and Bell, S. (2024). Mycobacteria acquisition from potable water. TSANZSRS 2024 The Australia & New Zealand Society of Respiratory Science and The Thoracic Society of Australia and New Zealand (ANZSRS/TSANZ) Annual Scientific Meeting for Leaders in Lung Health & Respiratory Science,, Gold Coast, QLD, Australia, 22-26 March 2024. Richmond, VIC, Australia: John Wiley & Sons. doi: 10.1111/resp.14673

Mycobacteria acquisition from potable water

2024

Conference Publication

Identification of Staphylococcus aureus hypermutator strain through metagenomic sputum analysis

Taylor, S., Bryant, J., Kyany'a, C., Duplancic, C., Sims, S., Elms, L., Thomson, R., Rogers, G., Bell, S. and Investigators, A. (2024). Identification of Staphylococcus aureus hypermutator strain through metagenomic sputum analysis. TSANZSRS 2024 The Australia & New Zealand Society of Respiratory Science and The Thoracic Society of Australia and New Zealand (ANZSRS/TSANZ) Annual Scientific Meeting for Leaders in Lung Health & Respiratory Science, Adelaide, SA, Australia, 22–26 March 2024. Richmond, VIC, Australia: John Wiley & Sons.

Identification of Staphylococcus aureus hypermutator strain through metagenomic sputum analysis

2024

Conference Publication

Nontuberculous mycobacteria (NTM) in Australians with cystic fibrosis (CF): A national study

Duplancic, C., Wainwright, C., Thomson, R., Rogers, G., Clements, A., Floto, R. and Bell, S. (2024). Nontuberculous mycobacteria (NTM) in Australians with cystic fibrosis (CF): A national study. TSANZSRS 2024 The Australia & New Zealand Society of Respiratory Science and The Thoracic Society of Australia and New Zealand (ANZSRS/TSANZ) Annual Scientific Meeting for Leaders in Lung Health & Respiratory Science, Adelaide, SA, Australia, 22–26 March 2024. Richmond, VIC, Australia: John Wiley & Sons.

Nontuberculous mycobacteria (NTM) in Australians with cystic fibrosis (CF): A national study

2023

Conference Publication

In vitro susceptibility testing of imipenem- relebactam and tedizolid against australian mycobacterium abscessus isolates

Burke, A. J., Carter, R., Tolson, C., Congdon, J., Duplancic, C., Bursle, E., Bell, S., Roberts, J. and Thomson, R. (2023). In vitro susceptibility testing of imipenem- relebactam and tedizolid against australian mycobacterium abscessus isolates. ATS 2023 International Conference, Washington, DC USA, 19-24 May 2023. Washington, DC USA: American Thoracic Society. doi: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2968

In vitro susceptibility testing of imipenem- relebactam and tedizolid against australian mycobacterium abscessus isolates

2023

Conference Publication

A method for the isolation of environmental Mycobacterium species from soil and house dust

Carter, R. M., Huygens, F. and Thomson, R. (2023). A method for the isolation of environmental Mycobacterium species from soil and house dust. International Conference of the American Thoracic Society (ATS) 2023, Washington, DC, United States, 19 - 24 May 2023. New York, NY, United States: American Thoracic Society. doi: 10.1164/ajrccm-conference.2023.207.1_MeetingAbstracts.A3594

A method for the isolation of environmental Mycobacterium species from soil and house dust